MA49463A - Vaccin contre le virus de l'herpès simplex - Google Patents

Vaccin contre le virus de l'herpès simplex

Info

Publication number
MA49463A
MA49463A MA049463A MA49463A MA49463A MA 49463 A MA49463 A MA 49463A MA 049463 A MA049463 A MA 049463A MA 49463 A MA49463 A MA 49463A MA 49463 A MA49463 A MA 49463A
Authority
MA
Morocco
Prior art keywords
herpes simplex
simplex vaccine
vaccine
herpes
simplex
Prior art date
Application number
MA049463A
Other languages
English (en)
Inventor
Andrew J Bett
Danilo R Casimiro
Giuseppe Ciaramella
Shinu John
Dai Wang
Lan Zhang
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA49463A publication Critical patent/MA49463A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA049463A 2017-04-26 2018-04-25 Vaccin contre le virus de l'herpès simplex MA49463A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762490067P 2017-04-26 2017-04-26

Publications (1)

Publication Number Publication Date
MA49463A true MA49463A (fr) 2021-05-05

Family

ID=63919141

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049463A MA49463A (fr) 2017-04-26 2018-04-25 Vaccin contre le virus de l'herpès simplex

Country Status (4)

Country Link
US (1) US20200054737A1 (fr)
EP (1) EP3641810A4 (fr)
MA (1) MA49463A (fr)
WO (1) WO2018200737A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3134131B1 (fr) 2014-04-23 2021-12-22 ModernaTX, Inc. Vaccins à base d'acide nucléique
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
ES2922760T3 (es) 2015-10-22 2022-09-20 Modernatx Inc Vacunas de virus respiratorios
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
US11643441B1 (en) 2015-10-22 2023-05-09 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
WO2017070616A2 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre les maladies sexuellement transmissibles
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
RS63336B1 (sr) 2015-12-10 2022-07-29 Modernatx Inc Kompozicije i postupci za isporuku terapijskih agenasa
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
ES2928475T3 (es) 2016-09-14 2022-11-18 Modernatx Inc Composiciones de ARN de alta pureza y métodos para su preparación
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (fr) 2016-12-08 2018-06-14 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
EP3555289A1 (fr) 2016-12-13 2019-10-23 ModernaTX, Inc. Purification par affinité d'arn
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170256A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170347A1 (fr) 2017-03-17 2018-09-20 Modernatx, Inc. Vaccins à base d'arn contre des maladies zoonotiques
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
AU2018316811B2 (en) 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
EP3668971B8 (fr) 2017-08-18 2024-05-29 ModernaTX, Inc. Variants d'arn polymérase
EP3668979A4 (fr) 2017-08-18 2021-06-02 Modernatx, Inc. Procédés pour analyse par clhp
EP3675817A1 (fr) 2017-08-31 2020-07-08 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
WO2019055807A1 (fr) 2017-09-14 2019-03-21 Modernatx, Inc. Vaccins à arn contre le virus zika
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
CN109337868B (zh) * 2018-06-28 2022-04-19 武汉滨会生物科技股份有限公司 利用vak技术在体外激活免疫细胞的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
WO2021015987A1 (fr) * 2019-07-19 2021-01-28 Merck Sharp & Dohme Corp. Polypeptides de glycoprotéines e antigéniques, compositions et leurs procédés d'utilisation
JP2021185136A (ja) 2020-04-22 2021-12-09 ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング コロナウイルスワクチン
EP4171629A1 (fr) * 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4032546A1 (fr) * 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Vaccin viral thérapeutique
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2023107999A2 (fr) * 2021-12-08 2023-06-15 Modernatx, Inc. Vaccins à arnm contre le virus de l'herpès simplex
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
JP2001508649A (ja) * 1996-11-04 2001-07-03 スミスクライン・ビーチャム・コーポレイション ２型単純ヘルペスウイルス由来の新規コーディング配列
AU781598B2 (en) * 1999-04-21 2005-06-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
WO2008011609A2 (fr) * 2006-07-20 2008-01-24 Vical Incorporated Compositions et méthodes de vaccination contre le hsv-2
US20130028925A1 (en) * 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
BR112013008700B8 (pt) * 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
CN103827131B (zh) * 2011-01-31 2017-06-30 宾夕法尼亚大学托管会 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法
NZ616304A (en) * 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AU2012322704B2 (en) * 2011-10-11 2017-09-07 Novartis Ag Recombinant self-replicating polycistronic RNA molecules
SI2850431T1 (en) * 2012-05-16 2018-08-31 Immune Design Corp. Vaccine against HSV-2
EP3134131B1 (fr) * 2014-04-23 2021-12-22 ModernaTX, Inc. Vaccins à base d'acide nucléique
US20170298389A1 (en) * 2014-10-10 2017-10-19 Vaxart, Inc. Hsv vaccines
AU2016324310B2 (en) * 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN108472355A (zh) * 2015-10-22 2018-08-31 摩登纳特斯有限公司 单纯疱疹病毒疫苗
WO2017070616A2 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre les maladies sexuellement transmissibles
WO2018081638A1 (fr) * 2016-10-27 2018-05-03 The Trustees Of The University Of Pennsylvania Arn à nucléoside modifié destiné à induire une réponse immunitaire adaptative
WO2018170256A1 (fr) * 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
AU2018316811B2 (en) * 2017-08-17 2023-07-13 The Trustees Of The University Of Pennsylvania Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

Also Published As

Publication number Publication date
US20200054737A1 (en) 2020-02-20
WO2018200737A1 (fr) 2018-11-01
EP3641810A4 (fr) 2021-08-18
EP3641810A1 (fr) 2020-04-29

Similar Documents

Publication Publication Date Title
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
MA46024A (fr) Vaccin contre le virus de l'herpès simplex
MA50813A (fr) Vaccins contre le virus d'epstein-barr
MA46584A (fr) Vaccin contre le cytomégalovirus humain
MA47787A (fr) Vaccin contre le virus respiratoire syncytial
MA46316A (fr) Vaccin contre le cytomégalovirus humain
EP3595676A4 (fr) Vaccins à base d'arn contre des maladies zoonotiques
MA43762A (fr) Vaccin contre le rsv
MA46317A (fr) Vaccin contre le virus respiratoire syncytial
EP3324979A4 (fr) Vaccins contre une maladie infectieuse
GB2592769B (en) CpG-Adjuvanted SARS-CoV-2 virus vaccine
EP3309251A4 (fr) Vecteur viral de parainfluenza de type 2 humain et vaccin
HK1258252A1 (zh) 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途
ZA202004538B (en) Influenza virus vaccines and uses thereof
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
GB201910794D0 (en) Vaccine
EP3866847A4 (fr) Vaccin antiviral
EP3139745B8 (fr) Vaccins contre les infections de l'herpès simplex génital
EP3500280A4 (fr) Vaccins contre des virus
HK1216988A1 (zh) 用於治療單純皰疹病毒 型感染的治療性疫苗
GB201811382D0 (en) Vaccine
AU2018903913A0 (en) Virus Vaccine
GB201818307D0 (en) HIV Vaccine
GB201818308D0 (en) HIV Vaccine
SG11202011004RA (en) Hepatitis b vaccine transnasal administration system